Goal #8: Foster the development of the emerging field of translational science

Date: Monday, September 30 - Tuesday, October 1, 2024Location: Southwest Virginia Higher Education Center in Abingdon, VirginiaHosted by:&nbsp;iTHRIV and Virginia Cooperative ExtensionTheme: Navigating the Changing Health Landscape in Appalachia&nbsp;Join us as we delve into crucial discussions surrounding the dynamic and evolving health landscape in the Appalachian region. With a focus on innovative strategies and collaborative approaches, this summit aims to address pressing challenges and explore opportunities for enhancing healthcare delivery and outcomes.&nbsp;Learn more about the event <a href="https://appalachianresearchnetwork.org/ATRN-2024-Annual-Health-Summit" target="_blank" rel="noopener noreferrer">here</a>.Register for the event <a href="https://appalachianresearchnetwork.org/event-5691818" target="_blank" rel="noopener noreferrer">here</a> by September 9, 2024.

Not affiliated with any listed CTSA hubs

large_ATRN Register Now.png

medium_ATRN Register Now.png

small_ATRN Register Now.png

thumbnail_ATRN Register Now.png

ATRN Register Now.png

Other

Appalachian Translational Research Network Annual Health Summit

- Any -

Goal #4: Improve clinical research

Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patients with hepatocellular carcinoma, the most common type of liver cancer, according to a clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and its Convergence Institute.&nbsp;The study will be published April 7 in Nature Medicine, with findings also presented at 1:30 p.m. PT at the annual meeting of the American Association for Cancer Research.&nbsp;Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Fewer than one in 10 patients survive five years post-diagnosis. Existing immune therapies such as PD-1 immune checkpoint inhibitors, aimed at releasing restraints cancer cells place on the immune system, have limited effects…&nbsp;Read the full article <a href="https://ictr.johnshopkins.edu/news_announce/personalized-vaccine-for-liver-cancer-shows-promise-in-clinical-trial-2/" target="_blank" rel="noopener noreferrer">here</a>.

Johns Hopkins Institute for Clinical and Translational Research

medium_News-May9.jpg

small_News-May9.jpg

thumbnail_News-May9.jpg

News-May9.jpg

Johns Hopkins University

Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial

X-logo-teal_80x66.png

ri_linkedin_fill_408497d4b5_96748f4451.png

Julio Pimentel, Ph.D., Miami Clinical &amp; Translational Science Institute ’18, is nationally recognized for transforming patient care through innovative research in therapy-resistant cancers and raising cancer awareness among underserved populations.&nbsp;Dr. Pimentel is a first-generation Mexican American, and his desire to serve as a liaison between the Hispanic community and the medical field began at an early age. He was a teenager when his volunteer experience at a local hospital inspired him to pursue a Ph.D. in cancer research. Most of the cancer patients were from underrepresented communities, and he recognized a disparity in their health care. He also questioned the effectiveness of certain treatments.&nbsp;“I wanted to understand why some tumors were responsive to treatment and others were not,” said Dr. Pimentel, a postdoctoral fellow at the University of California San Diego. “I also felt a responsibility to help the underserved…”&nbsp;Read the full article <a href="https://miamictsi.org/mscti/mscti-julio-pimentel/" target="_blank" rel="noopener noreferrer">here</a>.

CTSA CCOS

Home

About

CTSA Groups and Meetings

Resources

News

Help

CTSA News

Date

Share this News Post

Appalachian Translational Research Network Annual Health Summit